The radiotherapy developer, which is exploiting UChicago research, has now raised $264m in funding overall.
Reflexion Medical, a US-based cancer therapy developer partially based on research at University of Chicago, completed a $100m funding round yesterday led by Canadian pension fund manager Public Sector Pension Investment Board.
Pfizer Ventures and Johnson & Johnson Innovation – JJDC, subsidiaries of pharmaceutical firms Pfizer and Johnson & Johnson respectively, also took part in the round, as did KCK Group, Sofinnova Partners, Venrock, T. Rowe Price and TPG’s Rise Fund.
Reflexion is developing biology-guided radiotherapy technology in…
